All agents mentioned above have shown preclinical in vitro and in vivo antitumor efficacy in models of NSCLC harboring C797S and common activating EGFR mutations, with or without T790M [89,90,91,92]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.